Additionally, limited myocardial utilization of FAs (due to mitochondrial and autophagy functioning failure) in diabetes contributes to myocardial dysfunction, potentially explaining the improved outcomes in heart failure with diabetes seen with SGLT-2 inhibitors, which increase ketone bodies and provide an alternative energy source to the failing heart [9,19]. Here, SLC5A2 is linked to diabetes mellitus.